Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Interest Expenses (2020 - 2024)

Seres Therapeutics (MCRB) has disclosed Interest Expenses for 5 consecutive years, with $618000.0 as the latest value for Q1 2024.

  • Quarterly Interest Expenses fell 68.28% to $618000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $618000.0 through Dec 2024, down 87.96% year-over-year, with the annual reading at $2.5 million for FY2023, 59.0% down from the prior year.
  • Interest Expenses hit $618000.0 in Q1 2024 for Seres Therapeutics, down from $3.2 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $3.2 million in Q2 2023 to a low of $618000.0 in Q1 2024.
  • Historically, Interest Expenses has averaged $1.2 million across 5 years, with a median of $744000.0 in 2021.
  • Biggest five-year swings in Interest Expenses: surged 154.74% in 2022 and later tumbled 68.28% in 2024.
  • Year by year, Interest Expenses stood at $759000.0 in 2020, then fell by 2.77% to $738000.0 in 2021, then soared by 154.74% to $1.9 million in 2022, then soared by 69.52% to $3.2 million in 2023, then crashed by 80.61% to $618000.0 in 2024.
  • Business Quant data shows Interest Expenses for MCRB at $618000.0 in Q1 2024, $3.2 million in Q2 2023, and $1.9 million in Q1 2023.